株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アレルギー性鼻炎治療薬の世界市場:2020年~2024年

Global allergy rhinitis drugs market 2020-2024

発行 TechNavio (Infiniti Research Ltd.) 商品コード 500858
出版日 ページ情報 英文 120 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.95円で換算しております。
アレルギー性鼻炎治療薬の世界市場:2020年~2024年 Global allergy rhinitis drugs market 2020-2024
出版日: 2020年03月17日 ページ情報: 英文 120 Pages
概要

世界のアレルギー性鼻炎治療薬市場は、2020年から2024年の予測期間中に4%のCAGRで成長し、24億米ドルの規模に達する見込みです。アレルギー性鼻炎の有病率の増加が主な市場成長要因となっています。また、アレルギー性鼻炎に対する意識が高まることによって、更に市場成長が促進される見通しです。

当レポートでは、世界のアレルギー鼻炎治療薬市場について調査分析し、市場規模および成長率、市場動向、市場促進要因、課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

エグゼクティブサマリー

市場情勢

市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模:2019年
  • 市場の見通し:2019-2024年の予測

ファイブフォース分析

製品別市場セグメンテーション

  • 市場セグメンテーション
  • 製品別比較:市場規模と予測2019-2024
  • 抗ヒスタミン剤
  • 鼻腔内コルチコステロイド
  • 免疫療法
  • その他
  • 製品別の市場機会

顧客情勢

  • 概要

地域別情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模と予測2019-2024
  • 北米
  • 欧州
  • アジア太平洋地域
  • 南米
  • 中東・アフリカ地域
  • 主要国
  • 地域別の市場機会

成長要因、課題、および動向

  • 市場成長要因
  • 数量的成長要因-需要主導型成長
  • 数量的成長要因-供給主導型成長
  • 数量的成長要因-外部要因
  • 数量的成長要因-隣接市場での需要シフト
  • 価格上昇要因-インフレ
  • 価格上昇要因-低価格ユニットから高価格ユニットへの移行
  • 市場の課題
  • 市場動向

ベンダー情勢

  • 概要
  • 情勢の革新

ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • Alcon Inc.
  • ALK-Abello AS
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Stallergenes Greer Ltd.

付録

目次
Product Code: IRTNTR41321

Technavio has been monitoring the global allergy rhinitis drugs market 2020-2024 and it is poised to grow by USD 2.4 bn during 2020-2024, progressing at a CAGR of 4% during the forecast period. Our reports on global allergy rhinitis drugs market 2020-2024 provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of allergic rhinitis. In addition, increasing awareness about allergic rhinitis is anticipated to boost the growth of the global allergy rhinitis drugs market 2020-2024 as well.

Market Segmentation

Technavio's ‘ global allergy rhinitis drugs market 2020-2024 ’ is segmented as below:

Product:

  • Antihistamines
  • Intranasal Corticosteroids
  • Immunotherapies
  • Others

Geographic segmentation

  • APAC
  • Europe
  • MEA
  • North America
  • South America

Key Trends for global allergy rhinitis drugs market 2020-2024 growth

This study identifies increasing awareness about allergic rhinitis as the prime reasons driving the global allergy rhinitis drugs market 2020-2024 growth during the next few years.

Prominent vendors in global allergy rhinitis drugs market 2020-2024

We provide a detailed analysis of around 25 vendors operating in the global allergy rhinitis drugs market 2020-2024, including some of the vendors such as Alcon Inc., ALK-Abello AS, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi and Stallergenes Greer Ltd. .

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product placement
  • Antihistamines - Market size and forecast 2019-2024
  • Intranasal corticosteroids - Market size and forecast 2019-2024
  • Immunotherapies - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by Product

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • South America - Market size and forecast 2019-2024
  • MEA - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Volume driver - Demand shift in adjacent markets
  • Price driver - Inflation
  • Price driver - Shift from lower to higher-priced units
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Alcon Inc.
  • ALK-Abello AS
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Stallergenes Greer Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

List of Exhibits:

  • 1.Key Finding 1
  • 2.Key Finding 2
  • 3.Key Finding 3
  • 4.Key Finding 5
  • 5.Key Finding 6
  • 6.Key Finding 7
  • 7.Key Finding 8
  • 8.Market in focus
  • 10.Parent market
  • 13.Market characteristics
  • 15.Offerings of vendors included in the market definition
  • 17.Market segments
  • 22.Global - Market size and forecast 2019 - 2024 ($ million)
  • 23.Global market: Year-over-year growth 2019 - 2024 (%)
  • 24.Five forces analysis 2019 & 2024
  • 25.Bargaining power of buyers
  • 26.Bargaining power of suppliers
  • 27.Threat of new entrants
  • 28.Threat of substitutes
  • 29.Threat of rivalry
  • 30.Market condition - Five forces 2019
  • 31.Product placement - Market share 2019-2024 (%)
  • 32.Comparison by Product placement
  • 33.Antihistamines - Market size and forecast 2019-2024 ($ million)
  • 34.Antihistamines - Year-over-year growth 2019-2024 (%)
  • 35.Intranasal corticosteroids - Market size and forecast 2019-2024 ($ million)
  • 36.Intranasal corticosteroids - Year-over-year growth 2019-2024 (%)
  • 37.Immunotherapies - Market size and forecast 2019-2024 ($ million)
  • 38.Immunotherapies - Year-over-year growth 2019-2024 (%)
  • 39.Others - Market size and forecast 2019-2024 ($ million)
  • 40.Others - Year-over-year growth 2019-2024 (%)
  • 41. Market opportunity by Product
  • 42.Customer landscape
  • 43.Market share by geography 2019-2024 (%)
  • 44.Geographic comparison
  • 45.North America - Market size and forecast 2019-2024 ($ million)
  • 46.North America - Year-over-year growth 2019-2024 (%)
  • 47.Europe - Market size and forecast 2019-2024 ($ million)
  • 48.Europe - Year-over-year growth 2019-2024 (%)
  • 49.APAC - Market size and forecast 2019-2024 ($ million)
  • 50.APAC - Year-over-year growth 2019-2024 (%)
  • 51.South America - Market size and forecast 2019-2024 ($ million)
  • 52.South America - Year-over-year growth 2019-2024 (%)
  • 53.MEA - Market size and forecast 2019-2024 ($ million)
  • 54.MEA - Year-over-year growth 2019-2024 (%)
  • 55.Key leading countries
  • 56.Market opportunity by geography ($ million)
  • 57.Impact of drivers and challenges
  • 58.Vendor landscape
  • 60.Landscape disruption
  • 62.Industry risks
  • 64.Vendors covered
  • 66.Market positioning of vendors
  • 67.Alcon Inc. - Overview
  • 68.Alcon Inc. - Business segments
  • 69.Alcon Inc. - Key offerings
  • 70.Alcon Inc. - Key customers
  • 71.Alcon Inc. - Segment focus
  • 72.ALK-Abello AS - Overview
  • 73.ALK-Abello AS - Product and service
  • 74.ALK-Abello AS - Key offerings
  • 75.ALK-Abello AS - Key customers
  • 76.ALK-Abello AS - Segment focus
  • 77.Dr. Reddy's Laboratories Ltd. - Overview
  • 78.Dr. Reddy's Laboratories Ltd. - Business segments
  • 79.Dr. Reddy's Laboratories Ltd. - Key offerings
  • 80.Dr. Reddy's Laboratories Ltd. - Key customers
  • 81.Dr. Reddy's Laboratories Ltd. - Segment focus
  • 82.GlaxoSmithKline Plc - Overview
  • 83.GlaxoSmithKline Plc - Business segments
  • 84.GlaxoSmithKline Plc - Key offerings
  • 85.GlaxoSmithKline Plc - Key customers
  • 86.GlaxoSmithKline Plc - Segment focus
  • 87.Glenmark Pharmaceuticals Ltd. - Overview
  • 88.Glenmark Pharmaceuticals Ltd. - Product and service
  • 89.Glenmark Pharmaceuticals Ltd. - Key offerings
  • 90.Glenmark Pharmaceuticals Ltd. - Key customers
  • 91.Glenmark Pharmaceuticals Ltd. - Segment focus
  • 92.Merck & Co. Inc. - Overview
  • 93.Merck & Co. Inc. - Business segments
  • 94.Merck & Co. Inc. - Key offerings
  • 95.Merck & Co. Inc. - Key customers
  • 96.Merck & Co. Inc. - Segment focus
  • 97.Novartis AG - Overview
  • 98.Novartis AG - Business segments
  • 99.Novartis AG - Key offerings
  • 100.Novartis AG - Key customers
  • 101.Novartis AG - Segment focus
  • 102.Pfizer Inc. - Overview
  • 103.Pfizer Inc. - Business segments
  • 104.Pfizer Inc. - Key offerings
  • 105.Pfizer Inc. - Key customers
  • 106.Pfizer Inc. - Segment focus
  • 107.Sanofi - Overview
  • 108.Sanofi - Business segments
  • 109.Sanofi - Key offerings
  • 110.Sanofi - Key customers
  • 111.Sanofi - Segment focus
  • 112.Stallergenes Greer Ltd. - Overview
  • 113.Stallergenes Greer Ltd. - Product and service
  • 114.Stallergenes Greer Ltd. - Key offerings
  • 115.Stallergenes Greer Ltd. - Key customers
  • 116.Stallergenes Greer Ltd. - Segment focus
  • 118.Currency conversion rates for US$
  • 119.Research Methodology
  • 120.Validation techniques employed for market sizing
  • 121.Information sources
  • 122. List of abbreviations